{"entity":{"id":"carsten-denkert","kind":"person","name":"Carsten Denkert","aka":[],"tldr":"Pathologist who established tumour-infiltrating lymphocytes as a biomarker in breast cancer.","summary":"Carsten Denkert is Director of the Institute of Pathology at Philipps University Marburg and pathology lead for the German Breast Group (GBG). His specialisms are breast pathology, tumour-infiltrating lymphocytes and predictive biomarkers, using histopathology and immunohistochemistry. He is known for establishing tumour-infiltrating lymphocytes as a biomarker in breast cancer through analyses of GBG neoadjuvant trials, showing that stromal lymphocytes predict response to chemotherapy in triple-negative and HER2-positive disease. His Lancet Oncology paper pooled patients treated with neoadjuvant therapy to relate tumour-infiltrating lymphocytes to prognosis across breast cancer subtypes. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Denkert%20C%5BAuthor%5D%20tumor-infiltrating%20lymphocytes%20breast"}],"tags":[],"related":[],"cancers":["tnbc"],"sections":[],"technologies":["histopathology-ihc"],"targets":[],"drugs":[],"companies":["gbg"],"institutions":[],"pathways":[],"terms":["tils"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Institute of Pathology, Philipps University Marburg; GBG pathology lead","institutionId":"gbg","specialisms":["Breast pathology","Tumour-infiltrating lymphocytes","Predictive biomarkers"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Denkert%20C%5BAuthor%5D%20tumor-infiltrating%20lymphocytes%20breast"}],"papers":[{"title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","journal":"Lancet Oncology","year":2018,"doi":"10.1016/S1470-2045(17)30904-X"},{"title":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2112651","doi":"10.1056/NEJMoa2112651"}],"orcid":"0000-0002-2249-0982"},"route":"/people/carsten-denkert/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"histopathology-ihc","kind":"technology","name":"Histopathology & immunohistochemistry","route":"/technologies/histopathology-ihc/"}],"company":[{"id":"gbg","kind":"company","name":"German Breast Group (GBG)","route":"/companies/gbg/"}],"term":[{"id":"tils","kind":"term","name":"Tumour-infiltrating lymphocytes (TILs)","route":"/terms/tils/"}],"paper":[{"id":"paper-denkert-her2-low-pooled-neoadjuvant-lancet-oncol-2021","kind":"paper","name":"Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials","route":"/key-papers/paper-denkert-her2-low-pooled-neoadjuvant-lancet-oncol-2021/"},{"id":"paper-hahnen-geparsixto-germline-brca-jama-oncol-2017","kind":"paper","name":"Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial","route":"/key-papers/paper-hahnen-geparsixto-germline-brca-jama-oncol-2017/"},{"id":"paper-keynote-522-nejm-2022","kind":"paper","name":"KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer","route":"/key-papers/paper-keynote-522-nejm-2022/"},{"id":"paper-loibl-geparsixto-survival-hrd-ann-oncol-2018","kind":"paper","name":"Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto","route":"/key-papers/paper-loibl-geparsixto-survival-hrd-ann-oncol-2018/"},{"id":"paper-denkert-tils-neoadjuvant-pooled-lancet-oncol-2018","kind":"paper","name":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","route":"/key-papers/paper-denkert-tils-neoadjuvant-pooled-lancet-oncol-2018/"}],"institution":[{"id":"uct-frankfurt","kind":"institution","name":"University Cancer Center Frankfurt (UCT)","route":"/institutions/uct-frankfurt/"}]}}